PRME
Prime Medicine, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website rimemedicine.com
- Employees(FY) 175
- ISIN US74168J1016
Performance
+23.78%
1W
+34.35%
1M
-16.31%
3M
+15.12%
6M
-20.09%
YTD
-45.62%
1Y
Profile
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Investment Analysis Report: PRME
Overview
PRME is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $823,363,578. In this report, we will conduct a comprehensive analysis of PRME's financial statements to evaluate its valuation, financial health, earnings a...
Technical Analysis of PRME 2024-05-10
Overview:
In analyzing the technical indicators for PRME over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential invest...
Recent News & Updates
- 2024-05-16 18:27
- 2024-05-16 18:15
- 2024-05-16 07:14
- 2024-05-14 09:55
- 2024-05-13 21:55
- 2024-05-13 11:12
- 2024-05-13 08:00
- 2024-05-12 20:00
- 2024-05-12 03:00
Alphabet Bought Up Two Slumping Stocks(Barrons.com)
- 2024-05-11 09:02
- 2024-05-10 14:23
- 2024-05-10 08:00
- 2024-05-10 01:53
PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024(Investorplace)
- 2024-05-09 20:00
- 2024-05-08 08:00
- 2024-05-07 20:00
- 2024-05-03 12:00
- 2024-05-03 00:00
- 2024-05-01 08:00
- 2024-04-30 20:00
- 2024-04-30 06:01
Prime Medicine gets green light for trials of first-ever prime editing drug(Clinical Trials Arena)
- 2024-04-29 10:12
- 2024-04-29 07:35
- 2024-04-29 07:00
- 2024-04-28 19:33
- 2024-04-23 08:00
- 2024-04-22 20:00
- 2024-03-26 20:45
2 Magnificent Growth Stocks With Room to Run(Yahoo Finance)
- 2024-03-14 14:44
- 2024-03-01 14:00
Page 1 of 3
previousnext